Liquidia Co. (NASDAQ:LQDA - Get Free Report) insider Jason Adair sold 1,856 shares of the stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $25,185.92. Following the transaction, the insider now directly owns 184,304 shares of the company's stock, valued at approximately $2,501,005.28. This trade represents a 1.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Jason Adair also recently made the following trade(s):
- On Monday, January 27th, Jason Adair sold 445 shares of Liquidia stock. The stock was sold at an average price of $14.20, for a total transaction of $6,319.00.
Liquidia Stock Up 0.3 %
Shares of NASDAQ LQDA traded up $0.04 during trading hours on Friday, hitting $13.72. 597,870 shares of the stock were exchanged, compared to its average volume of 969,758. The firm has a fifty day moving average price of $14.65 and a 200-day moving average price of $12.80. The company has a market cap of $1.17 billion, a PE ratio of -8.42 and a beta of 0.23. Liquidia Co. has a 12 month low of $8.26 and a 12 month high of $16.81.
Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The company had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million. As a group, equities analysts anticipate that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Liquidia
Several institutional investors and hedge funds have recently added to or reduced their stakes in LQDA. GAMMA Investing LLC raised its position in shares of Liquidia by 65.6% during the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock valued at $44,000 after buying an additional 1,173 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in shares of Liquidia in the 4th quarter valued at $59,000. Summit Investment Advisors Inc. boosted its position in shares of Liquidia by 35.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after acquiring an additional 1,719 shares in the last quarter. D. E. Shaw & Co. Inc. acquired a new stake in Liquidia during the fourth quarter worth approximately $142,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Liquidia during the fourth quarter worth about $154,000. Institutional investors and hedge funds own 64.54% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on LQDA. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a research note on Thursday, March 20th. Scotiabank reiterated an "outperform" rating on shares of Liquidia in a research report on Thursday, March 20th. Finally, Needham & Company LLC reissued a "buy" rating and set a $25.00 price target on shares of Liquidia in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $26.63.
Get Our Latest Report on LQDA
Liquidia Company Profile
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
See Also
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
